ES2918589T3 - Inhibidores de bromodomios BET bicíclicos y usos de los mismos - Google Patents
Inhibidores de bromodomios BET bicíclicos y usos de los mismos Download PDFInfo
- Publication number
- ES2918589T3 ES2918589T3 ES16810193T ES16810193T ES2918589T3 ES 2918589 T3 ES2918589 T3 ES 2918589T3 ES 16810193 T ES16810193 T ES 16810193T ES 16810193 T ES16810193 T ES 16810193T ES 2918589 T3 ES2918589 T3 ES 2918589T3
- Authority
- ES
- Spain
- Prior art keywords
- dimethylisoxazol
- quinazolin
- alkyl
- mmol
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/84—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562259894P | 2015-11-25 | 2015-11-25 | |
| PCT/US2016/063485 WO2017091661A1 (en) | 2015-11-25 | 2016-11-23 | Bicyclic bet bromodomain inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2918589T3 true ES2918589T3 (es) | 2022-07-19 |
Family
ID=57543210
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16810193T Active ES2918589T3 (es) | 2015-11-25 | 2016-11-23 | Inhibidores de bromodomios BET bicíclicos y usos de los mismos |
| ES22162126T Active ES3011058T3 (en) | 2015-11-25 | 2016-11-23 | Bicyclic bet bromodomain inhibitors and uses thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES22162126T Active ES3011058T3 (en) | 2015-11-25 | 2016-11-23 | Bicyclic bet bromodomain inhibitors and uses thereof |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10508106B2 (enExample) |
| EP (2) | EP3380469B1 (enExample) |
| JP (2) | JP6882289B2 (enExample) |
| CN (2) | CN115806550B (enExample) |
| AU (3) | AU2016361441B2 (enExample) |
| CA (1) | CA3006300C (enExample) |
| ES (2) | ES2918589T3 (enExample) |
| WO (1) | WO2017091661A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108314680A (zh) * | 2017-01-16 | 2018-07-24 | 凯惠科技发展(上海)有限公司 | 一种含芳环化合物、其制备方法、药物组合物及应用 |
| CN109111426B (zh) * | 2017-06-23 | 2021-12-14 | 中国科学院上海药物研究所 | 一类稠合双环杂芳基或芳基化合物，及其用途 |
| WO2019201296A1 (zh) * | 2018-04-18 | 2019-10-24 | 南京明德新药研发有限公司 | 作为rho激酶抑制剂的吡唑类化合物 |
| EP3620164A1 (en) * | 2018-09-05 | 2020-03-11 | Genoscience Pharma SAS | Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins b (ctsb), l (ctsl) and d (ctsd) related diseases |
| WO2020219168A1 (en) | 2019-04-24 | 2020-10-29 | Convergene, Llc | Small molecule bromodomain inhibitors and uses thereof |
| KR102923602B1 (ko) * | 2019-05-31 | 2026-02-06 | 키에시 파르마슈티시 엣스. 피. 에이. | P2x3 억제제로서 피리도피리미딘 유도체 |
| MA56022A (fr) | 2019-05-31 | 2022-04-06 | Chiesi Farm Spa | Dérivés d'amino quinazoline servant d'inhibiteurs de p2x3 |
| CA3196287A1 (en) * | 2020-10-20 | 2022-04-28 | Binhua Lv | Substituted benzo or pyridopyrimidine amine inhibitor, preparation method therefor, and application thereof |
| CN117279914A (zh) * | 2021-01-29 | 2023-12-22 | 南京再明医药有限公司 | Sos1抑制剂及其制备方法和应用 |
| WO2022171018A1 (zh) * | 2021-02-09 | 2022-08-18 | 苏州泽璟生物制药股份有限公司 | 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用 |
| EP4291195A4 (en) * | 2021-02-11 | 2025-07-09 | Medical College Wisconsin Inc | SMALL MOLECULE INHIBITORS OF PBRM1-BD2 |
| EP4317157A4 (en) * | 2021-03-26 | 2025-04-09 | Medshine Discovery Inc. | 6-carbamate substituted heteroaryl ring derivatives |
| TW202416953A (zh) * | 2022-08-26 | 2024-05-01 | 日商衛材R&D企管股份有限公司 | 抗體藥物複合物 |
| WO2024235225A1 (zh) * | 2023-05-15 | 2024-11-21 | 苏州泽璟生物制药股份有限公司 | 取代嘧啶并环类抑制剂及其制备方法和应用 |
| WO2025209570A1 (zh) * | 2024-04-03 | 2025-10-09 | 北京大学 | Bet抑制剂及其应用 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3755332A (en) * | 1971-07-01 | 1973-08-28 | Ciba Geigy Corp | Substituted 4 indazolaminoquinolines |
| GB8908229D0 (en) * | 1989-04-12 | 1989-05-24 | Smithkline Beckman Intercredit | Compounds |
| CA2114727C (en) * | 1991-08-02 | 1996-12-10 | Mikel P. Moyer | Quinoline derivatives as immunostimulants |
| WO1999011658A1 (en) * | 1997-08-29 | 1999-03-11 | Proteus Molecular Design Ltd. | Meta-benzamidine derivatives as serin protease inhibitors |
| EP2048142A3 (en) * | 2001-04-26 | 2009-04-22 | Eisai R&D Management Co., Ltd. | Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof |
| SE0102858D0 (sv) * | 2001-08-27 | 2001-08-27 | Astrazeneca Ab | N-type calcium channel antagonists for the treatment of pain |
| US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| CA2557433C (en) * | 2004-02-19 | 2013-05-14 | Rexahn Corporation | Quinazoline derivatives and therapeutic use thereof |
| AU2006216266C1 (en) * | 2005-02-23 | 2010-08-26 | Shionogi & Co., Ltd. | Quinazoline derivative having tyrosine kinase inhibitory activity |
| CR9465A (es) * | 2005-03-25 | 2008-06-19 | Surface Logix Inc | Compuestos mejorados farmacocineticamente |
| US20090221624A1 (en) * | 2005-05-06 | 2009-09-03 | Olivo Paul D | 4-aminoquinoline compounds for treating virus-related conditions |
| CA2700988A1 (en) * | 2006-09-27 | 2008-05-08 | Surface Logix, Inc. | Rho kinase inhibitors |
| WO2008089307A2 (en) * | 2007-01-18 | 2008-07-24 | Lexicon Pharmaceuticals, Inc. | Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer |
| US20080200458A1 (en) * | 2007-01-18 | 2008-08-21 | Joseph Barbosa | Methods and compositions for the treatment of body composition disorders |
| GB0705915D0 (en) * | 2007-03-28 | 2007-05-09 | Helperby Therapeutics Ltd | New use |
| US8003787B2 (en) * | 2007-05-24 | 2011-08-23 | Bayer Schering Pharma Ag | Sulphoximine-substituted quinoline and quinazoline derivatives as kinase inhibitors |
| AU2008321959B2 (en) * | 2007-11-12 | 2014-02-13 | Msd K.K. | Heteroaryloxy quinazoline derivative |
| EP2072502A1 (de) * | 2007-12-20 | 2009-06-24 | Bayer Schering Pharma Aktiengesellschaft | Sulfoximid-substituierte Chinolin- und Chinazolinderivate als Kinase-Inhibitoren |
| WO2010056758A1 (en) * | 2008-11-12 | 2010-05-20 | Yangbo Feng | Quinazoline derivatives as kinase inhibitors |
| US20110135655A1 (en) * | 2009-01-13 | 2011-06-09 | PHILADELPHIA HEALTH AND EDUCATION CORPORATION d/b/a Drexel University College of Medicine; | Role of PI3K p110 delta Signaling in Retroviral Infection and Replication |
| GB0919423D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| AR079814A1 (es) * | 2009-12-31 | 2012-02-22 | Otsuka Pharma Co Ltd | Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos |
| JP2013526484A (ja) * | 2010-05-07 | 2013-06-24 | グラクソ グループ リミテッド | キナーゼ阻害剤としてのアミノ‐キノリン |
| US8933096B2 (en) * | 2010-06-09 | 2015-01-13 | Rugers, The State University of New Jersey | Antimicrobial agents |
| EP2603502B1 (en) * | 2010-08-13 | 2014-07-30 | Janssen Pharmaceutica, N.V. | 4-aminoquinazolin-2-yl-1-pyrrazole-4-carboxylic acid compounds as prolyl hydroxylase inhibitors |
| WO2012040499A2 (en) * | 2010-09-22 | 2012-03-29 | Surface Logix, Inc. | Metabolic inhibitors |
| CN103648500B (zh) * | 2011-03-17 | 2016-05-04 | 宾夕法尼亚大学理事会 | 双功能酶制钳型分子的方法和用途 |
| GB201106799D0 (en) * | 2011-04-21 | 2011-06-01 | Glaxosmithkline Llc | Novel compounds |
| BR112013033417A2 (pt) * | 2011-06-29 | 2016-08-16 | Otsuka Pharma Co Ltd | compostos terapêuticos e métodos relacionados de uso |
| WO2013086229A1 (en) * | 2011-12-07 | 2013-06-13 | Amgen Inc. | Bicyclic aryl and heteroaryl sodium channel inhibitors |
| US20130225611A1 (en) * | 2011-12-09 | 2013-08-29 | The Regents Of The University Of California | Compositions and Methods for Reducing Cancer Cell Proliferation and Modulating Importin-Beta Function |
| US20130281397A1 (en) * | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
| US9201821B2 (en) * | 2012-09-27 | 2015-12-01 | Apple Inc. | Interrupt timestamping |
| JP6457942B2 (ja) * | 2012-10-05 | 2019-01-23 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Ｇｄｆ−８阻害剤 |
| US9977024B2 (en) * | 2012-12-09 | 2018-05-22 | The Scripps Research Institute | Targeted covalent probes and inhibitors of proteins containing redox-sensitive cysteines |
| WO2014100501A1 (en) * | 2012-12-20 | 2014-06-26 | Sanford-Burnham Medical Research Institute | Small molecule agonists of neurotensin receptor 1 |
| EA201591746A1 (ru) * | 2013-03-14 | 2016-08-31 | КОНВЕРДЖЕН ЭлЭлСи | Способы и композиции для ингибирования бромодомен-содержащих белков |
| CN105473581B (zh) * | 2013-06-21 | 2019-04-23 | 齐尼思表观遗传学有限公司 | 作为溴结构域抑制剂的新取代的双环化合物 |
| CA2919948C (en) * | 2013-07-31 | 2020-07-21 | Zenith Epigenetics Corp. | Novel quinazolinones as bromodomain inhibitors |
| WO2015112739A1 (en) * | 2014-01-22 | 2015-07-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compounds and method for treating parp1-deficient cancers |
| JP6767875B2 (ja) * | 2014-04-08 | 2020-10-14 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Ｔｇｆ−ベータ阻害剤としての２，３−二置換ピリジン化合物および使用方法 |
| WO2015191568A2 (en) * | 2014-06-09 | 2015-12-17 | Biomed Valley Discoveries, Inc. | Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature |
| WO2015200534A2 (en) * | 2014-06-25 | 2015-12-30 | Sanford-Burnham Medical Research Institute | Small molecule agonists of neurotensin receptor 1 |
| US10106507B2 (en) * | 2014-08-03 | 2018-10-23 | H. Lee Moffitt Cancer Center and Research Insitute, Inc. | Potent dual BRD4-kinase inhibitors as cancer therapeutics |
| WO2016120808A1 (en) * | 2015-01-28 | 2016-08-04 | Minoryx Therapeutics S.L. | Heteroarylaminoisoquinolines, methods for their preparation and therapeutic uses thereof |
| EP3072891A1 (en) * | 2015-03-24 | 2016-09-28 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | New Toll-Like Receptor 9 Antagonists |
| CN108290855A (zh) * | 2015-07-01 | 2018-07-17 | 西北大学 | 被取代的喹唑啉化合物及其调节葡糖脑苷脂酶活性的用途 |
-
2016
- 2016-11-23 EP EP16810193.9A patent/EP3380469B1/en active Active
- 2016-11-23 US US15/779,353 patent/US10508106B2/en active Active
- 2016-11-23 CN CN202211334125.9A patent/CN115806550B/zh active Active
- 2016-11-23 ES ES16810193T patent/ES2918589T3/es active Active
- 2016-11-23 WO PCT/US2016/063485 patent/WO2017091661A1/en not_active Ceased
- 2016-11-23 CA CA3006300A patent/CA3006300C/en active Active
- 2016-11-23 AU AU2016361441A patent/AU2016361441B2/en active Active
- 2016-11-23 ES ES22162126T patent/ES3011058T3/es active Active
- 2016-11-23 EP EP22162126.1A patent/EP4050005B1/en active Active
- 2016-11-23 JP JP2018527799A patent/JP6882289B2/ja active Active
- 2016-11-23 CN CN201680079771.1A patent/CN109641886B/zh active Active
-
2019
- 2019-11-15 US US16/685,128 patent/US11028079B2/en active Active
-
2021
- 2021-05-06 JP JP2021078741A patent/JP7112567B2/ja active Active
- 2021-07-28 AU AU2021209257A patent/AU2021209257B2/en active Active
-
2024
- 2024-03-22 AU AU2024201890A patent/AU2024201890B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN109641886A (zh) | 2019-04-16 |
| US11028079B2 (en) | 2021-06-08 |
| CA3006300A1 (en) | 2017-06-01 |
| AU2016361441B2 (en) | 2021-08-12 |
| AU2021209257B2 (en) | 2023-12-21 |
| CA3006300C (en) | 2024-02-27 |
| JP2021119188A (ja) | 2021-08-12 |
| EP4050005A1 (en) | 2022-08-31 |
| CN109641886B (zh) | 2022-11-18 |
| AU2024201890B2 (en) | 2026-06-18 |
| AU2016361441A1 (en) | 2018-06-21 |
| EP4050005B1 (en) | 2024-12-25 |
| EP3380469B1 (en) | 2022-03-16 |
| US20180305344A1 (en) | 2018-10-25 |
| AU2024201890A1 (en) | 2024-05-16 |
| CN115806550B (zh) | 2025-11-28 |
| CN115806550A (zh) | 2023-03-17 |
| US20200223836A1 (en) | 2020-07-16 |
| JP2019501140A (ja) | 2019-01-17 |
| WO2017091661A1 (en) | 2017-06-01 |
| ES3011058T3 (en) | 2025-04-07 |
| JP7112567B2 (ja) | 2022-08-03 |
| AU2021209257A1 (en) | 2021-08-19 |
| EP3380469A1 (en) | 2018-10-03 |
| US10508106B2 (en) | 2019-12-17 |
| JP6882289B2 (ja) | 2021-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7112567B2 (ja) | 二環式ｂｅｔブロモドメイン阻害剤及びその使用 | |
| CN111542523B (zh) | 作为prmt5抑制剂的杂环化合物 | |
| ES2935746T3 (es) | Inhibidores de desmetilasa-1 específica de lisina | |
| ES2904544T3 (es) | Compuestos de indazol como inhibidores de la cinasa FGFR, preparación y uso de los mismos | |
| ES2997111T3 (en) | Pyridazinyl amino derivatives as alk5 inhibitors | |
| KR20170118688A (ko) | 브로모도메인 및 추가 말단 단백질의 저해를 위한 방법 및 조성물 | |
| CN114206883A (zh) | 氧代吡啶稠环衍生物及包含该衍生物的药物组合物 | |
| CN111918863B (zh) | 杂环化合物 | |
| EP4055013A1 (en) | Wdr5 inhibitors and modulators | |
| TWI532740B (zh) | ２－胺基－３－（咪唑－２－基）－吡啶－４－酮衍生物、其製備方法及其治療用途 | |
| CN120590414A (zh) | 一类含氮杂环类化合物、制备方法和用途 | |
| ES2929227T3 (es) | Piridopirimidinas como inhibidores del receptor de histamina H4 | |
| ES2802101T3 (es) | Compuestos de piridina heterocíclicos de cinco miembros y método de preparación y uso de los mismos | |
| ES2686828T3 (es) | Derivados de poliéteres macrocíclicos de N-aril-2-amino-4-aril-pirimidinas como inhibidores de la FLT3 y JAK | |
| HK40078733A (en) | Bicyclic bet bromodomain inhibitors and uses thereof | |
| HK40078733B (en) | Bicyclic bet bromodomain inhibitors and uses thereof | |
| HK1261992B (en) | Bicyclic bet bromodomain inhibitors and uses thereof | |
| HK1261992A1 (en) | Bicyclic bet bromodomain inhibitors and uses thereof | |
| CN113563341B (zh) | 作为Trk抑制剂的取代的吡唑并[1,5-a]嘧啶化合物 | |
| BR112017025356B1 (pt) | Composto, composição farmacêutica, e, uso para a fabricação de um medicamento |